Bavarian Nordic — November 2021
-
Zealand Pharma Announces Presentation of Preclinical Data on Amylin Analogue, ZP8396, and Clinical Data on Glucagon-GLP1 Dual-Agonist, BI 456906, at The Obesity Society Annual Meeting
-
“We are excited to debut preclinical data on our amylin analog, ZP8396, which holds potential as a treatment option in obesity both as a monotherapy and in combination with other drugs. When administered in combination with semaglutide, up to 20% weight loss in in vivo models was observed, which supports the initiation of a Phase 1 clinical study planned for later this quarter,” said Adam Steensberg, Executive Vice President and Chief Medical Officer at Zealand Pharma
-
“We are also thrilled to see Boehringer Ingelheim presenting the first clinical data on BI 456906, a GCGR/GLP1R dual agonist, where clinical data showed up to 13.7% weight loss following 16 weeks dosing in individuals with overweight/obesity and no unexpected safety issues were observed. The early data generated from these two programs highlight the potential of our growing investigational pipeline in obesity, an area in which we are committed to pioneering the development of novel treatments.”
-
(lige kommet i feed)
-
god aften:)
-
Bava: Bavarians topchef vil vippe Pfizer og Moderna af pinden https://borsen.dk/nyheder/virksomheder/bavarian-nordic-boss-vil-vippe-pfizer-af-pinden
-
Ja - og vil skabe et af de største vaccineselskaber i verden https://borsen.dk/nyheder/generelt/salget-skal-mere-end-tredobles-i-2025
-
Zealand Pharma vil præsenterer data fra potentielle vægttabsmidler https://www.proinvestor.com/investornyt/727332/zealand-pharma-vil-praesenterer-data-fra-potentielle-vaegttabsmidler
-
Tirsdagens aviser med Bavarian, Coloplast og Pandora https://www.proinvestor.com/investornyt/727617/tirsdagens-aviser-med-bavarian-coloplast-og-pandora
-
Mon ikke der bliver lidt interesse idag, efter skriverierne. De udtrykte i det mindste stor selvtillid, og man kan så begynde at spekulere i om der er noget på vej. Men tænker nu mere at opturen kommer senere hen
. Super at den er skortet så meget, det giver en god basis for en optur når den kommer. Aktien er billig efter min mening, selv om den er steget meget.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind